Literature DB >> 9657100

Allelic imbalance of insulin-like growth factor II gene expression in cancerous and precancerous lesions of the liver.

T Aihara1, S Noguchi, Y Miyoshi, H Nakano, Y Sasaki, Y Nakamura, M Monden, S Imaoka.   

Abstract

Allelic imbalance of the insulin-like growth factor II (IGF II) gene expression is often seen in hepatocellular carcinoma (HCC). To investigate the role of allelic imbalance in hepatocarcinogenesis, we have studied allelic expression status of the IGF II gene in dysplastic nodules, which are precancerous lesions of HCC, as well as in HCCs of different histological grade, and the influence of the allelic imbalance on IGF II gene expression has also been examined. Allelic imbalance was observed in 3 of 7 dysplastic nodules, in 7 of 9 well-differentiated HCCs, and in 8 of 9 moderately differentiated HCCs. IGF II gene expression level, which was studied by a semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR), was significantly higher (3.6-fold) in the dysplastic nodules than the control livers, but a significant increase in the IGF II gene expression was not observed in well- and moderately differentiated HCCs as compared with the control livers. These results demonstrate that the allelic imbalance of the IGF II gene expression is seen in the early stage (precancerous lesions) of hepatocarcinogenesis. Association of the allelic imbalance with an increased expression of the IGF II gene in the precancerous lesions might suggest a possible involvement of an IGF II autocrine loop in the pathogenesis of these lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657100     DOI: 10.1002/hep.510280113

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma.

Authors:  Philippe Couvert; Alain Carrié; Jacques Pariès; Jenny Vaysse; Audrey Miroglio; Antoine Kerjean; Pierre Nahon; Jamel Chelly; Jean-Claude Trinchet; Michel Beaugrand; Nathalie Ganne-Carrié
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

2.  Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma.

Authors:  Zhi-Zhen Dong; Deng-Fu Yao; Deng-Bing Yao; Xin-Hua Wu; Wei Wu; Li-Wei Qiu; Dao-Rong Jiang; Jian-Hua Zhu; Xian-Yong Meng
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

Review 3.  The IGF axis and hepatocarcinogenesis.

Authors:  J G Scharf; F Dombrowski; G Ramadori
Journal:  Mol Pathol       Date:  2001-06

4.  Hypoglycemia, an atypical early sign of hepatocellular carcinoma.

Authors:  Marialuisa Sorlini; Federica Benini; Primarosa Cravarezza; Giuseppe Romanelli
Journal:  J Gastrointest Cancer       Date:  2010-09

5.  Characterization of insulin-like-growth factor II (IGF II) mRNA positive hepatic altered foci and IGF II expression in hepatocellular carcinoma during diethylnitrosamine-induced hepatocarcinogenesis in rats.

Authors:  Biswajit Mukherjee; Shampa Ghosh; Tanushree Das; Manika Doloi
Journal:  J Carcinog       Date:  2005-08-10

6.  Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis.

Authors:  N Sedlaczek; A Hasilik; P Neuhaus; D Schuppan; H Herbst
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

7.  Differential Expression of Glypican-3 and Insulin–Like Growth Factor-II mRNAs and Alpha-Fetoprotein and Ki-67 Markers in HCV Related Hepatocellular Carcinomas In Egyptian Patients

Authors:  Mohamed A Saber; Samah MM AbdelHafiz; Fatma E Khorshed; Tarek S Aboushousha; Hussam EM Hamdy; Mohamed I Seleem; Amira H Soliman
Journal:  Asian Pac J Cancer Prev       Date:  2017-01-01

8.  IGF-II induced by hepatitis B virus X protein regulates EMT via SUMO mediated loss of E-cadherin in mice.

Authors:  Hye-Lin Ha; Taeho Kwon; In Seon Bak; Raymond L Erikson; Bo Yeon Kim; Dae-Yeul Yu
Journal:  Oncotarget       Date:  2016-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.